As­traZeneca teams up with Deep Mat­ter for AI drug de­vel­op­ment; Can­cer biotech Im­munOs rais­es $15M

As­traZeneca is align­ing it­self with the big da­ta com­pa­ny Deep­Mat­ter, which is fo­cused on at­tain­ing re­pro­ducibil­i­ty in chem­istry. The lat­ter is set to help the British drug­mak­er im­prove its com­pound syn­the­sis pro­duc­tiv­i­ty by us­ing an AI-pow­ered plat­form to cap­ture re­al-time da­ta to track fac­tors such as tem­per­a­ture, pres­sure, ul­tra­vi­o­let light lev­els and oth­er fac­tors in com­bi­na­tion with da­ta on sol­vents, cat­a­lysts, and reagents. “By cap­tur­ing in-situ chem­i­cal da­ta along­side the ex­per­i­men­tal in­tent, ob­ser­va­tions and out­comes, it is ex­pect­ed that ma­chine learn­ing and AI al­go­rithms could yield cost and time sav­ings whilst al­so pro­vid­ing nov­el in­sights in­to chem­istry,” the com­pa­nies said on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.